NDA 220210 · Ionis Pharms INC
Zanvastro
Zilganersen Sodium · Intrathecal
NovelPriority reviewOrphanCDER novel approval, Sep 3, 2026: To treat Alexander disease in pediatric and adult patients
Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2026
Sep 3, 2026
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 14, 2026.
ZANVASTRO is indicated for the treatment of Alexander disease in pediatric and adult patients. ZANVASTRO is a glial fibrillary acidic protein (GFAP)-directed antisense oligonucleotide indicated for the treatment of Alexander disease in pediatric and adult patients. ( 1 )
Mechanism: ZANVASTRO is an antisense oligonucleotide that causes degradation of glial fibrillary acidic protein (GFAP) pre-mRNA through binding to GFAP pre-mRNA, which results in a reduction of GFAP protein synthesis.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 3, 2026 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
- ZANVASTRO · ZILGANERSEN SODIUM EQ 56MG BASE/2.8ML (EQ 20MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zilganersen" as an intervention, any sponsor and status, largest first.
- A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)Pivotal-lookingActive, not recruiting
Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
NCT04849741 · 54 participants · Start Jun 1, 2021 · Primary completion Aug 22, 2025
Drug: zilganersen; Placebo · For: Alexander Disease
Sites: Palo Alto, California; Atlanta, Georgia; Boston, Massachusetts · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Ionis Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.